Wokelo AI’s Post

From hardcore athletes to weekend brunchers, more people are tracking blood sugar in real time. Henry Schein's (a Fortune 500 medical supplier) acquisition of Acentus (announced last week), indicates a larger opportunity at play. Several factors are driving growth and deal activity in a niche medical device category - Continuous Glucose Monitoring (or CGMs). We are witnessing… - Tech breakthroughs (wearables, needle-free tech, implantable sensors) - Regulatory approval for ‘Over-the-counter’ (Approved by FDA in 2023) - New segments unlocked (type-2 diabetes, athletes, wellness consumers) - Market structure rejig (surge in partnerships, insulin delivery integrations) However, what’s intriguing are the nature of recent partnerships (see chart) - Abbott has partnered with Medtronic (a direct competitor) to provide CGM for Medtronic’s smart-dosing equipment and software - Dexcom and Abbott, first 2 players to get OTC CGM device FDA approved - are going on the offense and forging alliances across the value chain - Abbott’s collaboration with Beta Bionics on an automated insulin delivery system underscores how CGMs are central to next-gen “bionic” solutions Which indiciates.. - An integrated ‘closed-loop’ ecosystem is being formed for insulin delivery and data-sharing. For use cases beyond diabetes management, that extend to nutrition and wellness. While forecasts project the CGM market to hit $16.7B by 2028 at a CAGR of ~19%; cost, insurance gaps, and data overload remain real hurdles. Yet new players are pushing the boundaries Especially around needle-free solutions, cutting-edge sensor tech and AI based insights on CGM - - Levels ($67M) backed by Andreessen Horowitz - Allez Health ($62.7M) backed by OSANG Healthcare US (OHC) - GlucoModicum Ltd ($33.5M) backed by European Innovation Council Fund - Spiden ($25M) backed by Ornament Health AG - Know Labs, Inc. ($12M) backed by Lind Capital Partners - Sava ($8M) backed by Balderton Capital As CGMs move from niche prescription devices to broad consumer wellness tools, expect even more capital infusions and partnerships aimed at truly closing the loop on diabetes management. Check out Wokelo.ai to perform bespoke investment analysis in minutes.